|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scher HI, Morris MJ, Kelly WK, Schwartz LH
and Heller G: Prostate cancer clinical trial end points:
‘RECIST’ing a step backwards. Clin Cancer Res. 11:5223–5232. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jacobs SC: Spread of prostatic cancer to
bone. Urology. 21:337–344. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DePuy V, Anstrom KJ, Castel LD, Schulman
KA, Weinfurt KP and Saad F: Effects of skeletal morbidities on
longitudinal patient-reported outcomes and survival in patients
with metastatic prostate cancer. Support Care Cancer. 15:869–876.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National comprehensive cancer network.
NCCN Clinical Practice Guidelines in Oncology: Prostate cancer.
http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Accessed May 23, 2013
|
|
6
|
Tefferi A: Polycythemia vera and essential
thrombocythemia: 2013 update on diagnosis, risk-stratification, and
management. Am J Hematol. 88:507–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Passamonti F: How I treat polycythemia
vera. Blood. 120:275–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spivak JL and Silver RT: The revised World
Health Organization diagnostic criteria for polycythemia vera,
essential thrombocytosis, and primary myelofibrosis: an alternative
proposal. Blood. 112:231–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barbui T, Barosi G, Birgegard G, et al:
Philadelphia-negative classical myeloproliferative neoplasms:
critical concepts and management recommendations from European
LeukemiaNet. J Clin Oncol. 29:761–770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gleason DF and Mellinger GT: Prediction of
prognosis for prostatic adenocarcinoma by combined histological
grading and clinical staging. J Urol. 111:58–64. 1974.PubMed/NCBI
|
|
12
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: Prostate. AJCC Cancer Staging Manual. 7th
edition. Springer; New York: pp. 457–468. 2010
|
|
13
|
Tombal B and Lecouvet F: Modern detection
of prostate cancer’s bone metastasis: Is the bone scan era over?
Adv Urol. 2012:8931932012. View Article : Google Scholar
|
|
14
|
Nørgaard M, Jensen AØ, Jacobsen JB, Cetin
K, Fryzek JP and Sørensen HT: Skeletal related events, bone
metastasis and survival of prostate cancer: a population based
cohort study in Denmark (1999 to 2007). J Urol. 184:162–167. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carlin BI and Andriole GL: The natural
history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer. 88(Suppl 12):
2989–2994. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briganti A, Passoni N, Ferrari M, et al:
When to perform bone scan in patients with newly diagnosed prostate
cancer: external validation of the currently available guidelines
and proposal of a novel risk stratification tool. Eur Urol.
57:551–558. 2010. View Article : Google Scholar
|
|
17
|
Lai MH, Luk WH and Chan JC: Predicting
bone scan findings using sPSA in patients newly diagnosed of
prostate cancer: feasibility in Asian population. Urol Oncol.
29:275–279. 2011. View Article : Google Scholar
|
|
18
|
Ho CC, Seong PK, Zainuddin ZM, Abdul Manaf
MR, Parameswaran M and Razack AH: Retrospective study of predictors
of bone metastasis in prostate cancer cases. Asian Pac J Cancer
Prev. 14:3289–3292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thompson I, Thrasher JB, Aus G, et al: AUA
Prostate Cancer Clinical Guideline Update Panel: Guideline for the
management of clinically localized prostate cancer: 2007 update. J
Urol. 177:2106–2131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heidenreich A, Aus G, Bolla M, et al:
European Association of Urology: EAU guidelines on prostate cancer.
Eur Urol. 53:68–80. 2008. View Article : Google Scholar
|
|
21
|
Koutsopoulos AV, Dambaki KI, Datseris G,
Giannikaki E, Froudarakis M and Stathopoulos E: A novel combination
of multiple primary carcinomas: urinary bladder transitional cell
carcinoma, prostate adenocarcinoma and small cell lung carcinoma -
report of a case and review of the literature. World J Surg Oncol.
3:512005. View Article : Google Scholar
|
|
22
|
Têtu B, Ro JY, Ayala AG, Johnson DE,
Logothetis CJ and Ordonez NG: Small cell carcinoma of the prostate.
Part I A clinicopathologic study of 20 cases. Cancer. 59:1803–1809.
1987. View Article : Google Scholar
|
|
23
|
Rubenstein JH, Katin MJ, Mangano MM,
Dauphin J, Salenius SA, Dosoretz DE and Blitzer PH: Small cell
anaplastic carcinoma of the prostate: seven new cases, review of
the literature, and discussion of a therapeutic strategy. Am J Clin
Oncol. 20:376–380. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seo Y, Shuke N, Yamamoto W, Usui K and
Aburano T: Sub-super bone scan caused by bone marrow involvement of
prostate cancer. Ann Nucl Med. 13:351–354. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tachev S, Ormanov I and Slavov CH: Cancer
of the prostate with metastasis to the bone marrow. Khirurgiia
(Sofiia). 39:96–97. 1986.(In Bulgarian).
|
|
26
|
Steiner RM, Mitchell DG, Rao VM, et al:
Magnetic resonance imaging of bone marrow: diagnostic value in
diffuse hematologic disorders. Magn Reson Q. 6:17–34.
1990.PubMed/NCBI
|
|
27
|
Birchall JD and O’Connor RA: Prostatic
metastases versus polycythemia on bone imaging. Clin Nucl Med.
29:375–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
